Marlboro maker Philip Morris International PM.N missed second-quarter revenue expectations on Tuesday with ZYN nicotine pouches sales disappointing
The tobacco company raised its fiscal-year profit guidance as it aims to generate two-thirds of its net revenue from smoking alternatives by 2030
Median PT of 18 brokerages covering the stock is $186 -data compiled by LSEG
MARKET REACTION OVERBLOWN
Morgan Stanley ("overweight," PT: $182) says with market over-reaction to short-term ZYN headwinds, the co is an attractive buy and holds highest long-term growth profile among mega-cap peers
Morningstar (fair value: $150) says PM remains market leader in many next-generation categories and stock drop reflects rationalization rather than performance weakness
Needham ("Buy," PT: $195) says while the co overshot on ZYN restocking, they remain positive with co's higher smoke-free mix compared with peers
BofA Global Research("buy," PO: $200) says PM remains a top performer for the year with stock decline on ZYN's U.S. volumes being overdone